Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Chemomab Therapeutics Ltd. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −3 vs. Q1 2025
- Shares held
- 4.23M
- +499.1K (+13.4%) vs. Q1 2025
- Total value
- $4.91M
- +$839.8K (+20.6%) vs. Q1 2025
- New holders
- 2
- 5 more added
- Sold out
- 5
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.07M |
| Q4 2023 | 16 | $1.43M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $58.7M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 1,614,134 | $1.87M | 0.00% | +1,496,974+1,277.7% | Added |
| OrbiMed Advisors LLC | 940,990 | $1.09M | 0.03% | −800,283−46.0% | Reduced |
| Sphera Funds Management Ltd. | 738,048 | $856.1K | 0.22% | −162,380−18.0% | Reduced |
| Yelin Lapidot Holdings Management Ltd. | 578,291 | $670.8K | 0.12% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 213,052 | $247.1K | 0.08% | 00.0% | Unchanged |
| Rhumbline Advisers | 39,875 | $46.2K | 0.00% | +16,026+67.2% | Added |
| Kestra Private Wealth Services, LLC | 31,241 | $36.2K | 0.00% | 00.0% | Unchanged |
| Boothbay Fund Management, LLC | 26,189 | $30.4K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 20,569 | $23.9K | 0.00% | +20,569 | New |
| BNP Paribas Arbitrage, SA | 13,900 | $16.1K | 0.00% | +3,400+32.4% | Added |
| GAMMA Investing LLC | 12,811 | $14.9K | 0.00% | +1,783+16.2% | Added |
| JPMorgan Chase & Co | 1,180 | $1.37K | 0.00% | +1,180 | New |
| UBS Group AG | 397 | $461 | 0.00% | −486−55.0% | Reduced |
| SBI Securities Co., Ltd. | 111 | $129 | 0.00% | +7+6.7% | Added |
| Virtu Financial LLC | 0 | $0 | 0.00% | −30,803−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −22,104−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −13,274−100.0% | Sold out |
| Wetzel Investment Advisors, Inc. | 0 | $0 | 0.00% | −11,000−100.0% | Sold out |
| Moser Wealth Advisors, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |